4.7 Article

PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?

Journal

INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 103, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.intimp.2021.108484

Keywords

Cervical cancer; Programmed cell death-ligand 1 (PD-L1); Immune-checkpoint inhibitor (ICI); Human papilloma virus (HPV)

Funding

  1. Natural Science Foundation of Liaoning Province of China [2019-MS-02]

Ask authors/readers for more resources

Cervical cancer, a major threat to women's health and lives worldwide, can be effectively treated with immunotherapy using PD-L1 inhibitors.
Cervical cancer is one of the most common in the female genital tract and remains a leading cause that threatens the health and lives of women worldwide, although preventive vaccines and early diagnosis have reduced mortality. While treatment by operation and chemoradiotherapy for early-stage patients achieve good outcomes, the great majority of cervical cancers caused by the human papilloma virus (HPV) make immunotherapy realizable for patients with advanced and recurrent cervical cancer. To date, some clinical trials of checkpoint immunotherapy in cervical cancer have indicated significant benefits of programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitors, providing strong evidence for PD-1/PD-L1 as a therapeutic target. In this review article, we discuss the role of PD-L1 and the application of PD-L1 inhibitors in cervical cancer, with the aim of providing direction for future research.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available